| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 26 | 2026 | 686 | 6.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 23 | 2026 | 1271 | 3.220 |
Why?
|
| Gastrointestinal Microbiome | 13 | 2026 | 831 | 3.110 |
Why?
|
| Gastrointestinal Diseases | 2 | 2026 | 337 | 1.340 |
Why?
|
| Dysbiosis | 5 | 2025 | 143 | 1.080 |
Why?
|
| Bacteria | 4 | 2026 | 519 | 1.040 |
Why?
|
| Bacteroides | 2 | 2024 | 36 | 1.030 |
Why?
|
| Feces | 4 | 2026 | 720 | 0.990 |
Why?
|
| Carbohydrate Metabolism | 1 | 2026 | 50 | 0.940 |
Why?
|
| Thrombospondins | 2 | 2018 | 14 | 0.680 |
Why?
|
| Metabolome | 2 | 2025 | 324 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 152 | 0.600 |
Why?
|
| Stem Cells | 4 | 2024 | 703 | 0.580 |
Why?
|
| Neutropenia | 3 | 2026 | 203 | 0.550 |
Why?
|
| Paneth Cells | 1 | 2017 | 22 | 0.540 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 54 | 0.490 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 290 | 0.490 |
Why?
|
| Transplantation, Homologous | 8 | 2024 | 666 | 0.480 |
Why?
|
| Intestines | 2 | 2017 | 587 | 0.470 |
Why?
|
| Smooth Muscle Tumor | 1 | 2014 | 2 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1313 | 0.410 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2014 | 31 | 0.410 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 20 | 0.410 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 36 | 0.410 |
Why?
|
| Animals | 20 | 2025 | 33817 | 0.400 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 163 | 0.400 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 72 | 0.400 |
Why?
|
| Mice | 17 | 2025 | 18214 | 0.390 |
Why?
|
| Vincristine | 1 | 2014 | 188 | 0.390 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 90 | 0.380 |
Why?
|
| Vaginal Neoplasms | 1 | 2012 | 17 | 0.360 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 309 | 0.350 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 2 | 0.330 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 5 | 0.330 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 657 | 0.330 |
Why?
|
| Colitis | 2 | 2023 | 165 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2010 | 59 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 95 | 0.320 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 471 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 2563 | 0.310 |
Why?
|
| Neoplasms | 2 | 2022 | 2960 | 0.310 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 1320 | 0.300 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2019 | 3 | 0.290 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 321 | 0.290 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 344 | 0.290 |
Why?
|
| Humans | 32 | 2026 | 130383 | 0.280 |
Why?
|
| Microbiota | 2 | 2025 | 437 | 0.270 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 326 | 0.270 |
Why?
|
| Middle Aged | 17 | 2026 | 28369 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2026 | 574 | 0.250 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 761 | 0.240 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1712 | 0.240 |
Why?
|
| Mucus | 2 | 2022 | 37 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 975 | 0.230 |
Why?
|
| Mucins | 2 | 2022 | 71 | 0.230 |
Why?
|
| Female | 23 | 2026 | 70344 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4715 | 0.220 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 8 | 0.220 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 311 | 0.220 |
Why?
|
| Bile Ducts | 1 | 2024 | 52 | 0.210 |
Why?
|
| Immunological Synapses | 1 | 2024 | 32 | 0.200 |
Why?
|
| Fever | 1 | 2026 | 309 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1362 | 0.200 |
Why?
|
| Xylose | 1 | 2022 | 6 | 0.190 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2023 | 108 | 0.190 |
Why?
|
| Carbapenems | 1 | 2022 | 46 | 0.180 |
Why?
|
| Biopsy | 2 | 2023 | 1241 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 452 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2022 | 146 | 0.170 |
Why?
|
| Stomach | 1 | 2024 | 269 | 0.170 |
Why?
|
| Fatal Outcome | 2 | 2014 | 356 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2015 | 589 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 145 | 0.170 |
Why?
|
| Adult | 12 | 2026 | 31130 | 0.170 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 227 | 0.170 |
Why?
|
| Vitamin A | 2 | 2019 | 57 | 0.170 |
Why?
|
| Organoids | 1 | 2024 | 301 | 0.170 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 2 | 0.170 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2021 | 2 | 0.170 |
Why?
|
| Filgrastim | 1 | 2020 | 13 | 0.160 |
Why?
|
| Glioma | 1 | 2025 | 508 | 0.160 |
Why?
|
| Aged | 12 | 2026 | 20860 | 0.160 |
Why?
|
| Methylamines | 1 | 2020 | 21 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.160 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 33 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 499 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 949 | 0.160 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 426 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1217 | 0.160 |
Why?
|
| Duodenal Diseases | 1 | 2020 | 28 | 0.160 |
Why?
|
| Ileal Diseases | 1 | 2020 | 26 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 125 | 0.150 |
Why?
|
| Leukemia | 1 | 2023 | 374 | 0.150 |
Why?
|
| Ileum | 1 | 2020 | 109 | 0.150 |
Why?
|
| Male | 16 | 2026 | 64424 | 0.150 |
Why?
|
| Interleukin-17 | 2 | 2022 | 125 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 220 | 0.150 |
Why?
|
| Duodenum | 1 | 2020 | 112 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 666 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 232 | 0.150 |
Why?
|
| Macrophages | 2 | 2020 | 661 | 0.140 |
Why?
|
| Japan | 2 | 2018 | 161 | 0.140 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 10 | 0.140 |
Why?
|
| WT1 Proteins | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2018 | 15 | 0.140 |
Why?
|
| Incidence | 1 | 2026 | 3316 | 0.140 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 15 | 0.140 |
Why?
|
| Cecum | 1 | 2018 | 26 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1586 | 0.140 |
Why?
|
| alpha-Defensins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 67 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4667 | 0.130 |
Why?
|
| Cytoprotection | 1 | 2017 | 37 | 0.130 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 107 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 57 | 0.130 |
Why?
|
| Metabolomics | 1 | 2021 | 501 | 0.130 |
Why?
|
| Lymphoma | 1 | 2020 | 328 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2018 | 142 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2017 | 226 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1384 | 0.120 |
Why?
|
| Remission Induction | 2 | 2018 | 304 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 9996 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 220 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2018 | 240 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2017 | 708 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 208 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 32 | 0.110 |
Why?
|
| Mannans | 1 | 2015 | 15 | 0.110 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 295 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2018 | 355 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2018 | 521 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 60 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 78 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 120 | 0.110 |
Why?
|
| Th17 Cells | 1 | 2015 | 97 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1319 | 0.100 |
Why?
|
| Allografts | 3 | 2020 | 218 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 65 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 53 | 0.100 |
Why?
|
| Homeostasis | 1 | 2018 | 714 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 955 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5163 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 204 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 239 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2013 | 62 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 437 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2025 | 373 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 611 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 287 | 0.090 |
Why?
|
| Prognosis | 3 | 2018 | 4859 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2014 | 500 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1481 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1279 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2015 | 396 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2020 | 17517 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1594 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1921 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 625 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2022 | 102 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2013 | 500 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2824 | 0.070 |
Why?
|
| Cyclosporine | 2 | 2019 | 131 | 0.070 |
Why?
|
| Mutation | 2 | 2021 | 6094 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2110 | 0.070 |
Why?
|
| Liposomes | 2 | 2019 | 197 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 481 | 0.060 |
Why?
|
| Fibrosis | 2 | 2019 | 418 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2023 | 1238 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2062 | 0.060 |
Why?
|
| Dioxoles | 1 | 2024 | 13 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 21 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 39 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 742 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 124 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2024 | 123 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 97 | 0.050 |
Why?
|
| Gene Library | 1 | 2024 | 211 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 18 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 31 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6439 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3753 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 54 | 0.050 |
Why?
|
| Machine Learning | 1 | 2026 | 381 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6200 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 188 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 478 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 353 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2022 | 3831 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 1 | 2021 | 3 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 706 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20723 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 640 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 901 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 105 | 0.040 |
Why?
|
| Atrophy | 1 | 2020 | 248 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1470 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 134 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 887 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 29 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 93 | 0.040 |
Why?
|
| Hair Follicle | 1 | 2018 | 31 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 21 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2017 | 42 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 44 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 62 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2023 | 759 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 122 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2019 | 125 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 811 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 161 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 336 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1788 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 274 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 257 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3711 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 899 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2012 | 12841 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1100 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 294 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 333 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1264 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 852 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 88 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 452 | 0.030 |
Why?
|
| Candidiasis | 1 | 2015 | 133 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10948 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 1017 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 632 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 525 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 766 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 550 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1206 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2295 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1807 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2900 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2553 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6786 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4673 | 0.020 |
Why?
|